OPNT - オピアント・ファ―マシュ―ティカルズ （Opiant Pharmaceuticals Inc.） オピアント・ファ―マシュ―ティカルズOPNTのチャート
OPNTの企業情報
| symbol | OPNT |
|---|---|
| 会社名 | Opiant Pharmaceuticals Inc （オピアント・ファ―マシュ―ティカルズ） |
| 分野（sector） | Basic Industries 素材 |
| 産業（industry） | Precious Metals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Opiant Pharmaceuticals Inc. formerly Lightlake Therapeutics Inc. is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray a treatment to reverse opioid overdoses which was conceived licensed developed and approved by the United States Food and Drug Administration (FDA). The Company's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED) a treatment for Bulimia Nervosa (BN) a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities. オピアント・ファ―マシュ―ティカルズは米国の専門製薬会社。主に薬物使用、中毒、摂食障害に対する治療法の開発に従事する。オピオイド系鎮痛剤の過剰摂取をリバ―スさせるナロキソン塩酸塩「NARCAN」鼻腔用スプレ―を開発。同社製品候補には過食症治療薬、コカイン使用障害治療薬、ヘロインワクチンが含まれる。本社所在地はカリフォルニア州サンタ・モニカ。 Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. |
| 本社所在地 | 201 Santa Monica Boulevard Suite 500 Santa Monica CA 90401 USA |
| 代表者氏名 | Michael J. Sinclair マイケル・シンクレア |
| 代表者役職名 | Executive Chairman of the Board 取締役会長 |
| 電話番号 | +1 310-598-5410 |
| 設立年月日 | 38504 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 14人 |
| url | www.lightlaketherapeutics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/opnt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -9.08382 |
| 終値（lastsale） | 17.27 |
| 時価総額（marketcap） | 63701206.69 |
| 時価総額 | 時価総額（百万ドル） 58.81564 |
| 売上高 | 売上高（百万ドル） 16.61532 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 47.57064 |
| 当期純利益 | 当期純利益（百万ドル） -9.36162 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Opiant Pharmaceuticals Inc revenues totaled $4.9M. Net loss totaled to $10.7M. Results are not comparable due to year end change. |
OPNTのテクニカル分析
OPNTのニュース
Indivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science Portfolio 2023/03/03 13:06:13 Benzinga
Indivior PLC (OTCPK:INVVY) (LSE:INDV) has completed the acquisition of Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) The transaction strengthens Indivior''s addiction treatment and science portfolio by adding Opiant''s late-stage assets, notably OPNT003, an investigational opioid overdose treatment designed to offer an important treatment option to address the current wave of US opioid overdoses from powerful synthetic opioids, such as fentanyl. Financial Consideration On November 13, 2022, Indivior and Opiant entered into a definitive agreement under which Indivior would acquire Opiant for an upfront consideration of $20.00 per share, in cash (approximately $145 million in aggregate), plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch. Following the closing of all customary conditions, the acquisition was completed on …
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc. 2023/03/02 15:14:00 PR Newswire
Combination Strengthens Indivior''s Addiction Treatment and Science Portfolio RICHMOND, Va., March 2, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) ("Indivior" or the "Company") today announced that it has completed the acquisition of Opiant Pharmaceuticals, Inc. ("Opiant"). The…
What''s The Opiant CVR Worth? (NASDAQ:OPNT) 2023/02/11 08:50:01 Seeking Alpha
Opiant appears on track to be acquired for $20/share and offers various CVRs linked to a potential drug launch. See why I rate OPNT stock a buy.
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC 2023/02/07 21:01:00 GlobeNewswire
SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the previously announced Merger Agreement (the Agreement) for Opiant to be acquired by Indivior PLC (LSE: INDV).
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC 2023/02/06 13:00:00 GlobeNewswire
SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC (LSE: INDV).
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2022 Results - Earnings Call Transcript 2022/08/12 13:10:08 Seeking Alpha
Opiant Pharmaceuticals, Inc. (NASDAQ:NASDAQ:OPNT) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Ben Atkins - VP Communications and Investor Relations…
Opiant Pharmaceuticals GAAP EPS of -$2.31 misses by $0.95, revenue of $3.89M misses by $0.77M 2022/08/11 20:39:04 Seeking Alpha
Opiant Pharmaceuticals press release (NASDAQ:OPNT): Q2 GAAP EPS of -$2.31 misses by $0.95.Revenue of $3.89M (-65.5% Y/Y) misses by $0.77M.
Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update 2022/08/11 20:05:00 GlobeNewswire
SANTA MONICA, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and six months ended June 30, 2022, and provided a corporate update. Recent highlights include:
Opiant Pharmaceuticals Q2 Earnings Preview (NASDAQ:OPNT) 2022/08/10 21:35:43 Seeking Alpha
Opiant Pharmaceuticals (OPNT) is scheduled to announce Q2 earnings results on Thursday, August 11th, after market close.The consensus EPS Estimate is -$1.36 and the consensus…
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful 2022/08/09 13:08:37 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy Mersana Therapeutics Inc (NASDAQ: MRSN ) announced a global collaboration that provides GSK plc (NYSE: GSK ) an exclusive option to co-develop and commercialize XMT-2056. Mersana will receive an upfront option purchase fee of $100 million. Mersana is also eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option. Mersana has retained options to profit-share and to co-promote in the U.S. Clearside Biomedical Secures Non-Dilutive fUNDING fROM HealthCare Royalty Partners Clearside Biomedical Inc (NASDAQ: CLSD ) has entered into a Royalty Interest Purchase and Sale Agreement with HealthCare Royalty Partners. Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million . At the same time, an additional $12.5 million will be deposited in an escrow account to be released to Clearside upon attainment of a pre-specified sales milestone for XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use.
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2022 Results - Earnings Call Transcript 2022/08/12 13:10:08 Seeking Alpha
Opiant Pharmaceuticals, Inc. (NASDAQ:NASDAQ:OPNT) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Ben Atkins - VP Communications and Investor Relations…
Opiant Pharmaceuticals GAAP EPS of -$2.31 misses by $0.95, revenue of $3.89M misses by $0.77M 2022/08/11 20:39:04 Seeking Alpha
Opiant Pharmaceuticals press release (NASDAQ:OPNT): Q2 GAAP EPS of -$2.31 misses by $0.95.Revenue of $3.89M (-65.5% Y/Y) misses by $0.77M.
Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update 2022/08/11 20:05:00 GlobeNewswire
SANTA MONICA, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and six months ended June 30, 2022, and provided a corporate update. Recent highlights include:
Opiant Pharmaceuticals Q2 Earnings Preview (NASDAQ:OPNT) 2022/08/10 21:35:43 Seeking Alpha
Opiant Pharmaceuticals (OPNT) is scheduled to announce Q2 earnings results on Thursday, August 11th, after market close.The consensus EPS Estimate is -$1.36 and the consensus…
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful 2022/08/09 13:08:37 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy Mersana Therapeutics Inc (NASDAQ: MRSN ) announced a global collaboration that provides GSK plc (NYSE: GSK ) an exclusive option to co-develop and commercialize XMT-2056. Mersana will receive an upfront option purchase fee of $100 million. Mersana is also eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option. Mersana has retained options to profit-share and to co-promote in the U.S. Clearside Biomedical Secures Non-Dilutive fUNDING fROM HealthCare Royalty Partners Clearside Biomedical Inc (NASDAQ: CLSD ) has entered into a Royalty Interest Purchase and Sale Agreement with HealthCare Royalty Partners. Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million . At the same time, an additional $12.5 million will be deposited in an escrow account to be released to Clearside upon attainment of a pre-specified sales milestone for XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use.